After accessing the NKO home page, a Sailor selects the 'career management' tab and navigates along the blue side banner and selects the Enlisted Learning and Development (LaDR
All rating-specific LaDRs
were developed by subject matter experts at the NETC learning centers and include input from the enlisted community managers at the Bureau of Naval Personnel and have been validated by the fleet.
Discussions begin at the lowest level at which LADRs
are completed and move upward.
platform integrates the company's proprietary linker chemistry with albumin biology to create anti-cancer molecules.
Besides credentialing information, the app also offers BIBs, LaDRs
, United Services Military Apprenticeship Program (USMAP) trades and rating information cards.
Since the LADR
drug candidates are albumin-binding drugs, the company believes the response rates will be higher in the selected patients who test positive with this personalized medicine companion diagnostic.
I strongly recommend that all Supply Departmental LCPOs add this LaDR
to their toolbox, in addition to their NOS-specific one.
"Sailors at all levels should familiarize themselves with their assigned LaDR
and seek guidance from their chain of command," Leahy added.
"Our companion diagnostic will offer physicians the ability to determine a cancer patient's unique physiological tumor characteristics and to use these distinctions to select albumin-based LADR
drug candidates that increase the likelihood of a successful outcome, while reducing the potential for possible adverse reactions," said Felix Kratz, PhD, Centurion Biopharma's Vice President of Drug Discovery and inventor of the companion diagnostic.
Board of directors of Ladder Capital Corp (NYSE: LADR
) has declared a second quarter 2018 dividend of USD 0.325 per share of Class A common stock, the company said.
The posters feature comprehensive and statistically significant efficacy data for the company's albumin binding ultra high potency LADR
drug candidates, LADR-7, LADR-8, LADR-9 and LADR-10.
The company is also expanding its pipeline of ultra-high potency oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR
(Linker Activated Drug Release) technology platform, a discovery engine designed to leverage its expertise in albumin biology and linker technology for the development of a new class of anti-cancer therapies.